Final Results from our Phase I Trial of ALN-TTR01

Final Results from our Phase I Trial of ALN-TTR01

Today, scientists presented final results from our Phase I clinical trial of ALN-TTRo1 at the XIII International Symposium on Amyloidosis held in Groningen. Data from this study show that administration of ALN-TTR01 resulted in statistically significant reductions in serum TTR protein levels, including both wild-type and mutant TTR protein, in ATTR patients.  Knockdown of TTR, the disease-causing protein, was found to be dose dependent, rapid, and durable after just a single dose.




ALN-TTR01 uses the identical siRNA as ALN-TTR02 our lead RNAi therapeutic for the treatment of ATTR, but ALN-TTR02 employs a proprietary second-generation LNP formulation that has demonstrated improved potency and tolerability based on pre-clinical and clinical studies.  ALN-TTR02 is currently being tested in a Phase I clinical study in normal healthy volunteers with results expected in the third quarter of 2012.  Further, the we expects to start a Phase II study of ALN-TTR02 in ATTR patients in the second half of 2012 and start pivotal studies in 2013.



SIGN UP FOR EMAIL UPDATES

Receive news and updates on the work at Alnylam that affects you most.